<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Androl Urol</journal-id><journal-id journal-id-type="iso-abbrev">Transl Androl Urol</journal-id><journal-id journal-id-type="publisher-id">TAU</journal-id><journal-title-group><journal-title>Translational Andrology and Urology</journal-title></journal-title-group><issn pub-type="epub">2223-4691</issn><publisher><publisher-name>AME Publishing Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4842573</article-id><article-id pub-id-type="publisher-id">tau-05-S1-AB037</article-id><article-id pub-id-type="doi">10.21037/tau.2016.s037</article-id><article-categories><subj-group subj-group-type="heading"><subject>Podium Lecture</subject></subj-group></article-categories><title-group><article-title>AB037. Icariside II improves human cavernous endothelial cells function by regulating miR-155/eNOS signal pathway</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guan</surname><given-names>Ruili</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Hongen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Bicheng</given-names></name></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Huixi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lin</given-names></name></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Yinglu</given-names></name></contrib><contrib contrib-type="author"><name><surname>Xin</surname><given-names>Zhongcheng</given-names></name></contrib><aff id="aff1">Andrology Center, Peking University First Hospital, Peking University, Beijing 100034, <country>China</country></aff></contrib-group><pub-date pub-type="epub-ppub"><month>4</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><volume>5</volume><issue>Suppl 1</issue><elocation-id>AB037</elocation-id><permissions><copyright-statement>2016 Translational Andrology and Urology. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Translational Andrology and Urology.</copyright-holder></permissions><abstract><sec><title>Background</title><p>To investigate the changes of miR-155/endothelial nitric oxide synthase (eNOS) signal pathway under the stimulation of age-BSA and glucose with or without icariside II (ICAII) intervention inhuman cavernous endothelial cells (HCECs).</p></sec><sec><title>Methods</title><p>Purified HCECs were first divided into three groups randomly: normal group + BSA (NC group), age-BSA + glucose group (DM group), ICAII treatment group (DM + ICAII group with different concentrations at 0.1, 1, 10 &#x000b5;M). Western Blot to detect the protein expression of eNOS and RAGE; real time PCR to detect the expression of miR-155 and eNOS; DAF-FM DA fluorescent probes assay and NaNO<sub>3</sub>/NaNO<sub>2</sub> assay to detect the NO concentration. Lentivirus mediated miR-155 over-expression was constructed to observe the changes of eNOS and NO.</p></sec><sec><title>Results</title><p>The eNOS and RAGE expression in DM group is significantly reduced and increased respectively compared with that of NC group (P&#x0003c;0.05), while ICAII intervention could reverse this change effectively. The 10 &#x000b5;M of ICAII has the most powerful effect. MiR-155 has the highest fold changes among candidate miRNAs in diabetic like HCECs (P&#x0003c;0.05). MiR-155 increased and eNOS decreased remarkably in DM group, while ICAII intervention could inhibit the miR-155 expression, which led to the significantly higher eNOS expression and NO concentration (P&#x0003c;0.05). In lentivirus mediated miR-155 overexpression with or without ICAII intervention model, we found the similar trend with the above diabetic model.</p></sec><sec><title>Conclusions</title><p>MiR-155/eNOS signal pathway may be involved in the process of diabetic HCECs dysfunction. ICAII could promote the recovery of the endothelial dysfunction by regulating the miR-155/eNOS signal pathway.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Erectile dysfunction</kwd><kwd>icariside II (ICAII)</kwd><kwd>miR-155</kwd><kwd>nitric oxide synthase (NOS)</kwd><kwd>endothelial dysfunction</kwd></kwd-group></article-meta></front></article>